by Team Small News | Apr 24, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Dasatinib Tablets in various strengths. The approved product is bioequivalent and therapeutically... by Team Small News | Apr 14, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a leading Indian pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for the generic equivalent of Xarelto (Rivaroxaban), a popular anticoagulant drug. The generic version, Rivaroxaban Tablets, will be used to... by Team Small News | Apr 12, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a generic drugmaker, has received final approval from the US FDA to manufacture and market Rivaroxaban Tablets USP in the strength of 2.5 mg. This approval is based on the company’s demonstration of bioequivalence and therapeutic equivalence to... by Team Small News | Apr 11, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has successfully completed a Phase 1 pharmacokinetics study for its investigational bone drug. The study aimed to evaluate the drug’s ability to maintain a stable level in the bloodstream over a prolonged...
by Team Small News | Apr 9, 2025 | Aurobindo Pharma, Pharma, Sun Pharma, Zydus
The US government, under President Donald Trump, has announced plans to impose new tariffs on pharmaceutical imports, which could significantly impact India, the top supplier of generic drugs to the US. The move aims to push pharmaceutical manufacturing back to the...
by Team Small News | Apr 1, 2025 | Aurobindo Pharma, Divi's Laboratories, Pharma, Sun Pharma, Torrent Pharma, Zydus
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as...